The Journal of infection
-
The Journal of infection · Aug 2020
Meta AnalysisEstimation of RAAS-Inhibitor effect on the COVID-19 outcome: A Meta-analysis.
Some studies of hospitalized patients suggested that the risk of death and/or severe illness due to COVID-19 is not associated with the use of angiotensin-converting enzyme inhibitors (ACEIs) and/or angiotensin II receptor type 1 blockers (ARBs). Nevertheless, some controversy still exists and there is limited information of the ACEIs/ARBs effect size on COVID-19 prognosis. ⋯ RAAS inhibitors might be associated with better COVID-19 prognosis.